Search

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine

First published: 28 August 2014

GSK update on current development status of the GSK/NIH Ebola vaccine candidate

GSK is working WHO to accelerate development of our investigational Ebola vaccine and to ramp up production as quickly as possible

First published: 18 October 2014

GSK statement on Oxford University phase I trial results of an Ebola candidate vaccine

Results from a phase I trial published by Oxford University show that a GSK/NIH Ebola vaccine demonstrated an acceptable safety profile

First published: 28 January 2015

GSK statement on first phase 1 trial results of a candidate Ebola vaccine

Results from phase 1 trial published in NEJM show that GSK/NIH Ebola candidate vaccine was well-tolerated in the 20 healthy adult volunteers

First published: 26 November 2014

GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute

Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines

First published: 06 August 2019

New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine

Consortium includes GSK and research partners from Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne and the Bernhard-Nocht

First published: 16 December 2014

Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial

Healthcare workers among those to be vaccinated in large-scale trial involving up to 30,000 people due to start in the coming weeks

First published: 23 January 2015

Annual Summary 2014

First published: 01 June 2022

GSK position on Technology transfer and local manufacturing

First published: 08 October 2025

Responsible Business Supplement 2014

First published: 18 March 2025